119 related articles for article (PubMed ID: 24529874)
21. Associations of insulin-like growth factor-I and its binding proteins and testosterone with frailty in older men.
Yeap BB; Paul Chubb SA; Lopez D; Ho KK; Hankey GJ; Flicker L
Clin Endocrinol (Oxf); 2013 May; 78(5):752-9. PubMed ID: 23009592
[TBL] [Abstract][Full Text] [Related]
22. Gender differences in the relation of insulin-like growth factor binding protein-1 to cardiovascular risk factors: a population-based study.
Undén AL; Elofsson S; Brismar K
Clin Endocrinol (Oxf); 2005 Jul; 63(1):94-102. PubMed ID: 15963068
[TBL] [Abstract][Full Text] [Related]
23. [Subclinical hypothyroidism and the risk for cardiovascular diseases. Are epidemiological studies giving the right answers?].
Földes J; Winkler G
Orv Hetil; 2010 Sep; 151(37):1488-94. PubMed ID: 20807695
[TBL] [Abstract][Full Text] [Related]
24. Insulin-like growth factor-binding protein-3 (IGFBP-3) but not insulin-like growth factor-I (IGF-I) remains elevated in euthyroid TSH-suppressed Graves' disease.
Wan Nazaimoon WM; Khalid BA
Horm Metab Res; 1998 Apr; 30(4):213-6. PubMed ID: 9623636
[TBL] [Abstract][Full Text] [Related]
25. Relation between thyroid-stimulating hormone and the occurrence of cardiovascular events and mortality in patients with manifest vascular diseases.
Westerink J; van der Graaf Y; Faber DR; Spiering W; Visseren FL;
Eur J Prev Cardiol; 2012 Aug; 19(4):864-73. PubMed ID: 21724680
[TBL] [Abstract][Full Text] [Related]
26. Associations of anthropometric parameters with serum TSH, prolactin, IGF-I, and testosterone levels: results of the study of health in Pomerania (SHIP).
Friedrich N; Rosskopf D; Brabant G; Völzke H; Nauck M; Wallaschofski H
Exp Clin Endocrinol Diabetes; 2010 Apr; 118(4):266-73. PubMed ID: 19609846
[TBL] [Abstract][Full Text] [Related]
27. Testosterone and Cardiovascular Risk: Meta-Analysis of Interventional Studies.
Corona G; Rastrelli G; Di Pasquale G; Sforza A; Mannucci E; Maggi M
J Sex Med; 2018 Jun; 15(6):820-838. PubMed ID: 29803351
[TBL] [Abstract][Full Text] [Related]
28. Clinical implications of the reduced activity of the GH-IGF-I axis in older men.
Ceda GP; Dall'Aglio E; Maggio M; Lauretani F; Bandinelli S; Falzoi C; Grimaldi W; Ceresini G; Corradi F; Ferrucci L; Valenti G; Hoffman AR
J Endocrinol Invest; 2005; 28(11 Suppl Proceedings):96-100. PubMed ID: 16760634
[TBL] [Abstract][Full Text] [Related]
29. Hormonal markers of aging in men with laryngeal carcinoma.
Jóźków P; Medraś M; Krecicki T; Zalesska-Krecicka M
Head Neck; 2005 Mar; 27(3):243-7. PubMed ID: 15668928
[TBL] [Abstract][Full Text] [Related]
30. Comparative effects of DHEA vs. testosterone, dihydrotestosterone, and estradiol on proliferation and gene expression in human LNCaP prostate cancer cells.
Arnold JT; Le H; McFann KK; Blackman MR
Am J Physiol Endocrinol Metab; 2005 Mar; 288(3):E573-84. PubMed ID: 15536203
[TBL] [Abstract][Full Text] [Related]
31. Total insulinlike growth factor 1 and insulinlike growth factor binding protein levels, functional status, and mortality in older adults.
Kaplan RC; McGinn AP; Pollak MN; Kuller L; Strickler HD; Rohan TE; Xue X; Kritchevsky SB; Newman AB; Psaty BM
J Am Geriatr Soc; 2008 Apr; 56(4):652-60. PubMed ID: 18312313
[TBL] [Abstract][Full Text] [Related]
32. Effects of androgens on the cardiovascular system.
Rosano GM; Cornoldi A; Fini M
J Endocrinol Invest; 2005; 28(3 Suppl):32-8. PubMed ID: 16042358
[TBL] [Abstract][Full Text] [Related]
33. IGF-I and testosterone levels as predictors of bone mineral density in healthy, community-dwelling men.
Rucker D; Ezzat S; Diamandi A; Khosravi J; Hanley DA
Clin Endocrinol (Oxf); 2004 Apr; 60(4):491-9. PubMed ID: 15049965
[TBL] [Abstract][Full Text] [Related]
34. Lower plasma testosterone or dihydrotestosterone, but not estradiol, is associated with symptoms of intermittent claudication in older men.
Yeap BB; Alfonso H; Chubb SA; Handelsman DJ; Hankey GJ; Golledge J; Flicker L; Norman PE
Clin Endocrinol (Oxf); 2013 Nov; 79(5):725-32. PubMed ID: 23509861
[TBL] [Abstract][Full Text] [Related]
35. Thyroid function, cardiovascular events, and mortality in diabetic hemodialysis patients.
Drechsler C; Schneider A; Gutjahr-Lengsfeld L; Kroiss M; Carrero JJ; Krane V; Allolio B; Wanner C; Fassnacht M
Am J Kidney Dis; 2014 Jun; 63(6):988-96. PubMed ID: 24315768
[TBL] [Abstract][Full Text] [Related]
36. The effect of testosterone on cardiovascular disease: a critical review of the literature.
Su JJ; Park SK; Hsieh TM
Am J Mens Health; 2014 Nov; 8(6):470-91. PubMed ID: 24563500
[TBL] [Abstract][Full Text] [Related]
37. Cardiovascular disease and androgens: a review.
Kaushik M; Sontineni SP; Hunter C
Int J Cardiol; 2010 Jun; 142(1):8-14. PubMed ID: 19923015
[TBL] [Abstract][Full Text] [Related]
38. Testosterone deficiency and cardiovascular mortality.
Morgentaler A
Asian J Androl; 2015; 17(1):26-31. PubMed ID: 25432501
[TBL] [Abstract][Full Text] [Related]
39. Cardiovascular risks and elevation of serum DHT vary by route of testosterone administration: a systematic review and meta-analysis.
Borst SE; Shuster JJ; Zou B; Ye F; Jia H; Wokhlu A; Yarrow JF
BMC Med; 2014 Nov; 12():211. PubMed ID: 25428524
[TBL] [Abstract][Full Text] [Related]
40. Testosterone therapy and cardiovascular risk.
Walsh JP; Kitchens AC
Trends Cardiovasc Med; 2015 Apr; 25(3):250-7. PubMed ID: 25467243
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
